X

Trial Profile

A Phase 2b Open-Label Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01 in Study PTR-01-002

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PTR 01 (Primary)
Indications Epidermolysis bullosa dystrophica
Focus Adverse reactions; Therapeutic Use
Sponsors Phoenix Tissue Repair

Most Recent Events

08 Nov 2022 Status changed from recruiting to completed.
24 Mar 2022 Planned End Date changed from 30 Sep 2022 to 30 Nov 2022.
24 Mar 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com